Sermorelin
A growth hormone–releasing hormone analog once marketed as an approved drug; today it is available mainly through licensed compounding pharmacies, and whether it is currently eligible is a question for the pharmacy.
What it is
Sermorelin is a synthetic version of the first 29 amino acids of growth-hormone-releasing hormone — the active core of the natural molecule. Unusually for this library, it was once an FDA-approved drug (Geref, for pediatric GH deficiency) before being discontinued for commercial reasons rather than safety ones.
That history gives it more legitimate clinical pedigree than most 'anti-aging' peptides, and it survives today mainly through compounding-pharmacy channels in adult wellness programs. The open question isn't whether it releases GH — it does — but whether raising GH pulses in aging adults produces meaningful benefits, which the trials never established.
What researchers have actually studied it for
Pediatric growth-hormone deficiency (its former approved indication) and GH-axis diagnostics; adult anti-aging use is extrapolation.
How it works
GHRH(1-29) — the fragment carrying essentially all of the parent hormone's receptor activity. It stimulates the pituitary's own GH release in natural pulses, preserving the feedback loops that direct GH injection bypasses; its action is short, mimicking the physiological signal rather than flooding it.
The molecule itself
GHRH(1-29) — the shortest fragment retaining full receptor activity, 29 of the parent's 44 amino acids, unmodified. No stabilization, no lipidation: minutes of action mimicking a natural pulse, which is both its physiological virtue and its commercial obsolescence next to engineered successors.
Where it came from
Synthesized in the wake of GHRH's 1982 discovery, sermorelin became Geref, approved for diagnosing and treating pediatric GH deficiency. It was withdrawn from the US market in 2008 for business reasons, then found a second life as the compounding world's flagship 'GH optimization' peptide.
The timeline
1982
GHRH isolated (from a pancreatic tumor, in a classic endocrinology story); the 1-29 fragment follows.
1990s
Approved as Geref for pediatric GH deficiency and diagnostics.
2008
Withdrawn from the US market for commercial reasons.
2010s–now
Second life as compounding pharmacies' flagship 'GH optimization' peptide.
What the research record actually contains
- Pediatric GH-deficiency trials supporting its former approval.
- Diagnostic-use literature for GH-axis testing.
- Small adult studies showing raised GH/IGF-1 and exploratory endpoints in aging — hypothesis-level, never definitive.
- No controlled trials demonstrating body-composition, recovery or longevity outcomes in healthy adults.
What could change this assessment
No sponsor is developing it; its future is regulatory rather than scientific — compounding eligibility decisions determine availability. The adult-outcomes trial that would settle its wellness use remains unrun after two decades of market demand, which is itself the forecast.
What's known about risks
Its approved-era record was benign — injection-site reactions and flushing led the list. The unanswered question for wellness use is chronic-elevation safety in older adults: GH excess has known metabolic and proliferative risks, and no long-term trial has cleared casual use.
Where it stands legally
No current approved product; availability runs through compounding pharmacies, whose eligibility to prepare it is a live question only a licensed pharmacy can answer on a given day.
Worth asking a licensed provider
- 1.What specifically are we trying to change, and how will we measure it — IGF-1 alone isn't an outcome?
- 2.Which licensed pharmacy compounds it, and what's its current eligibility status?
- 3.What glucose and IGF-1 monitoring will we run, and what would make us stop?
Common claims, corrected
“It was banned.”
Reality: It was discontinued commercially — a business exit, not a safety action. The distinction matters and marketing on both sides blurs it.
“Adult 'GH optimization' inherits its pediatric evidence.”
Reality: Its trials treated childhood deficiency with defined diagnostics. Adult wellness use extrapolates across population, indication and endpoint simultaneously.
Sermorelin FAQ
Was sermorelin ever FDA-approved?
Yes — as Geref for pediatric GH deficiency, later withdrawn from the market for commercial reasons. Its current availability runs through compounding pharmacies, whose eligibility to prepare it is a question for the pharmacy.
Sermorelin vs HGH — what's the difference?
HGH is the hormone itself; sermorelin prompts your pituitary to release your own, preserving the body's pulsatile pattern and feedback loops. That's mechanistically gentler — and still unproven as an anti-aging strategy.
Does sermorelin reverse aging?
No trial shows that. It raises GH pulses; the chain from 'more GH pulses in older adults' to 'better aging outcomes' is hypothesis, and GH excess has known risks that make casual use unwise.
Sermorelin vs CJC-1295 — what's the practical difference?
Same receptor, opposite pharmacokinetics: sermorelin delivers minutes-long natural-style pulses; CJC-1295 with DAC parks a continuous signal for a week. The choice between pulse and plateau is the entire question.
Why do clinics still favor sermorelin?
Its former-approved-drug pedigree, benign old safety file and pulse-mimicking profile make it the easiest secretagogue to present respectably — pedigree that shouldn't be confused with adult-outcome evidence.